This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (99)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • Alert me on articles by topic  Social Bookmarking   What's this?

Jonathan B. Brown, MPP, PhD; Kathryn L. Pedula, MS; Alan W. Bakst, PharmD

Arch Intern Med. 1999;159:1873-1880.

Background  A substantial proportion of the costs of diabetes treatment arises from treating long-term complications, particularly cardiovascular and renal disease. However, little is known about the progressive cost of these complications. Firmer knowledge would improve diabetes modeling and might increase the financial and organizational support for the prevention of diabetic complications.

Methods  We analyzed 9 years of clinical data on 11,768 members of a large group-model health maintenance organization who had probable type 2 diabetes mellitus. We ascertained the presence of cardiovascular and renal complications, staged the members progression, and estimated their incremental costs by stage.

Results  We found no significant differences between men and women in the prevalence or staging of complications. Per-person costs increased over baseline ($2033) by more than 50% ($1087) after initiation of cardiovascular drug therapy and/or use of a cardiologist, and by 360% ($7352) after a major cardiovascular event. Abnormal renal function increased diabetes treatment costs by 65% ($1337); advanced renal disease, by 195% ($3979); and end-stage renal disease, by 771% ($15,675). Both cardiovascular and renal diseases were more common among older subjects, but age did not affect the additional costs of these complications. Women had substantially higher medical care costs after controlling for age and presence of complications. Incremental cost estimates based solely on "labeled" events significantly underestimate true incremental cost.

Conclusions  In an aggregate population, the greatest cost savings would be achieved by preventing major cardiovascular events. For individuals, the greatest savings would be achieved by preventing progression to stage 3 renal disease.

From the Kaiser Permanente Center for Health Research, Portland, Ore (Dr Brown and Ms Pedula); and SmithKline Beecham Pharmaceuticals, Collegeville, Pa (Dr Bakst).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(16):1961-1962.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
Delea et al.
J. Am. Soc. Nephrol. 2009;20:2205-2213.
ABSTRACT | FULL TEXT  

Development of life-expectancy tables for people with type 2 diabetes
Leal et al.
Eur Heart J 2009;30:834-839.
ABSTRACT | FULL TEXT  

Cure, Care, and Commitment: What Can We Look Forward To?
Rizza et al.
Diabetes Care 2008;31:1051-1059.
FULL TEXT  

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes
Wilding et al.
Diabetes and Vascular Disease Research 2007;4:194-203.
ABSTRACT  

Pharmacoeconomic Analysis of Angiotensin-Converting Enzyme Inhibitors in Type 2 Diabetes: A Markov Model
Campbell et al.
The Annals of Pharmacotherapy 2007;41:1101-1110.
ABSTRACT | FULL TEXT  

Higher Medical Care Costs Accompany Impaired Fasting Glucose
Nichols and Brown
Diabetes Care 2005;28:2223-2229.
ABSTRACT | FULL TEXT  

Hospitalizations, Nursing Home Admissions, and Deaths Attributable to Diabetes
Russell et al.
Diabetes Care 2005;28:1611-1617.
ABSTRACT | FULL TEXT  

Outcomes of Project Dulce: A Culturally Specific Diabetes Management Program
Gilmer et al.
The Annals of Pharmacotherapy 2005;39:817-822.
ABSTRACT | FULL TEXT  

Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis
Hoerger et al.
ANN INTERN MED 2004;140:689-699.
ABSTRACT | FULL TEXT  

Cost of Medical Care for Chronic Kidney Disease and Comorbidity among Enrollees in a Large HMO Population
Smith et al.
J. Am. Soc. Nephrol. 2004;15:1300-1306.
ABSTRACT | FULL TEXT  

Meta-Analysis of the Effect of Diabetes on Restenosis Rates Among Patients Receiving Coronary Angioplasty Stenting
Gilbert et al.
Diabetes Care 2004;27:990-994.
ABSTRACT | FULL TEXT  

Economic Consequences of Epidemiological Changes in Diabetes in Middle-Income Countries: The Mexican case
Arredondo and Zuniga
Diabetes Care 2004;27:104-109.
ABSTRACT | FULL TEXT  

Review: Diabetic dyslipidaemia -- the case for using statins
Gadsby
British Journal of Diabetes & Vascular Disease 2003;3:402-407.
ABSTRACT  

Setting evidence-based priorities for diabetes care improvement
O'Connor
Int J Qual Health Care 2003;15:283-285.
FULL TEXT  

The Direct Medical Cost of Type 2 Diabetes
Brandle et al.
Diabetes Care 2003;26:2300-2304.
ABSTRACT | FULL TEXT  

The cost of major comorbidity in people with diabetes mellitus
Simpson et al.
CMAJ 2003;168:1661-1667.
ABSTRACT | FULL TEXT  

Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study
Lamy et al.
Circulation 2003;107:960-965.
ABSTRACT | FULL TEXT  

Variation in Diabetes Care Among States: Do patient characteristics matter?
Arday et al.
Diabetes Care 2002;25:2230-2237.
ABSTRACT | FULL TEXT  

Does Diabetes Disease Management Save Money and Improve Outcomes? : A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria
Sidorov et al.
Diabetes Care 2002;25:684-689.
ABSTRACT | FULL TEXT  

The Impact of Cardiovascular Disease on Medical Care Costs in Subjects With and Without Type 2 Diabetes
Nichols and Brown
Diabetes Care 2002;25:482-486.
ABSTRACT | FULL TEXT  

Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design
Shea et al.
J. Am. Med. Inform. Assoc. 2002;9:49-62.
ABSTRACT | FULL TEXT  

Productivity and Medical Costs of Diabetes in a Large Employer Population
Ramsey et al.
Diabetes Care 2002;25:23-29.
ABSTRACT | FULL TEXT  

The Treatment of Hypertension in Adult Patients With Diabetes
Arauz-Pacheco et al.
Diabetes Care 2002;25:134-147.
FULL TEXT  

Cardiovascular Drug Use and Hospitalizations Attributable to Type 2 Diabetes
Erkens et al.
Diabetes Care 2001;24:1428-1432.
ABSTRACT | FULL TEXT  

Comorbidity and Glycemic Control in Patients With Type 2 Diabetes
El-Kebbi et al.
Arch Intern Med 2001;161:1295-1300.
ABSTRACT | FULL TEXT  

Health Care Use of Individuals With Diabetes in an Employer-Based Insurance Population
Laditka et al.
Arch Intern Med 2001;161:1301-1308.
ABSTRACT | FULL TEXT  

The National Diabetes Education Program, Changing the Way Diabetes Is Treated: Comprehensive diabetes care
Clark et al.
Diabetes Care 2001;24:617-618.
FULL TEXT  

Potential Short-Term Economic Benefits of Improved Glycemic Control: A managed care perspective
Menzin et al.
Diabetes Care 2001;24:51-55.
ABSTRACT | FULL TEXT